MEI Pharma, Inc. (MEIP)

Market Cap	18.49M
Revenue (ttm)	n/a
Net Income (ttm)	-46.60M
Shares Out	6.66M
EPS (ttm)	-6.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,605
Open	2.750
Previous Close	2.750
Day's Range	2.750 - 2.787
52-Week Range	2.610 - 6.910
Beta	0.64
Analysts	Hold
Price Target	7.00 (+152.25%)
Earnings Date	Nov 12, 2024

About MEIP

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 19, 2003
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: MEIP
• Website: https://meipharma.com

Analyst Forecast

According to 2 analysts, the average rating for MEIP stock is "Hold." The 12-month stock price forecast is $7.0, which is an increase of 152.25% from the latest price.

Price Target

$7.0

(152.25% upside)

Analyst Consensus: Hold